Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 34, pp. 3952-3964
Open Access | Times Cited: 244

Showing 1-25 of 244 citing articles:

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 3, pp. 609-617
Open Access | Times Cited: 281
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Antonio González‐Martín, Philipp Harter, Alexandra Léary, et al.
Annals of Oncology (2023) Vol. 34, Iss. 10, pp. 833-848
Open Access | Times Cited: 156
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I. Ray-Coquard, Alexandra Léary, Sandro Pignata, et al.
Annals of Oncology (2023) Vol. 34, Iss. 8, pp. 681-692
Open Access | Times Cited: 155
Clinical and translational advances in ovarian cancer therapy
Panagiotis A. Konstantinopoulos, Ursula A. Matulonis
Nature Cancer (2023) Vol. 4, Iss. 9, pp. 1239-1257
Closed Access | Times Cited: 125
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal, et al.
Annals of Oncology (2022) Vol. 33, Iss. 10, pp. 1021-1028
Open Access | Times Cited: 104
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Jonathan A. Ledermann, Xavier Matías‐Guiu, Frédéric Amant, et al.
Annals of Oncology (2024) Vol. 35, Iss. 3, pp. 248-266
Open Access | Times Cited: 101
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer
Ning Li, Jianqing Zhu, Rutie Yin, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1230-1230
Open Access | Times Cited: 91
PARP Inhibitors in Ovarian Cancer: A Review
David M. O’Malley, Thomas C. Krivak, Nashwa Kabil, et al.
Targeted Oncology (2023) Vol. 18, Iss. 4, pp. 471-503
Open Access | Times Cited: 77
PARP inhibitors: enhancing efficacy through rational combinations
Deepak Bhamidipati, Jaime Haro-Silerio, Timothy A. Yap, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 6, pp. 904-916
Open Access | Times Cited: 73
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Éric Pujade-Lauraine, Frédèric Selle, Giovanni Scambia, et al.
Annals of Oncology (2023) Vol. 34, Iss. 12, pp. 1152-1164
Open Access | Times Cited: 68
Heterogeneity and treatment landscape of ovarian carcinoma
Ana Veneziani, Eduardo González-Ochoa, Husam Alqaisi, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 820-842
Closed Access | Times Cited: 65
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Antonio González‐Martín, Bhavana Pothuri, Ignace Vergote, et al.
European Journal of Cancer (2023) Vol. 189, pp. 112908-112908
Open Access | Times Cited: 62
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 981-992
Open Access | Times Cited: 34
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Alvina I. Khamidullina, Yaroslav E. Abramenko, Alexandra V. Bruter, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1263-1263
Open Access | Times Cited: 19
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
Giorgio Bogani, Kathleen Moore, I. L. Ray-Coquard, et al.
Gynecologic Oncology (2025) Vol. 193, pp. 30-40
Closed Access | Times Cited: 7
The evolving landscape of antibody-drug conjugates in gynecologic cancers
Anthony W. Tolcher, Erika Hamilton, Robert L. Coleman
Cancer Treatment Reviews (2023) Vol. 116, pp. 102546-102546
Closed Access | Times Cited: 30
PARP Inhibitors in Breast and Ovarian Cancer
Samuel Sherng Young Wang, Yeo Ee Jie, Sim Wey Cheng, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2357-2357
Open Access | Times Cited: 28
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions
Giuseppe Caruso, Federica Tomao, Gabriella Parma, et al.
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 4, pp. 431-443
Open Access | Times Cited: 27
Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data
Michael Friedlander, Yeh Chen Lee, William P. Tew
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 27
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
Vikas Garg, Amit M. Oza
Drugs (2023) Vol. 83, Iss. 15, pp. 1365-1385
Open Access | Times Cited: 27
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Domenica Lorusso, Marie‐Ange Mouret‐Reynier, Philipp Harter, et al.
International Journal of Gynecological Cancer (2023) Vol. 34, Iss. 4, pp. 550-558
Open Access | Times Cited: 27
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
European Journal of Cancer (2023) Vol. 188, pp. 131-139
Closed Access | Times Cited: 25
How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
Martina Arcieri, Veronica Tius, Claudia Andreetta, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
Xiaohua Wu, Jihong Liu, Jing Wang, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1612-1621
Closed Access | Times Cited: 13
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Tira J. Tan, Sarah Sammons, Young‐Hyuck Im, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 7, pp. 1240-1247
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top